leisure time -WSS

leisure time

author：hotspot 2025-10-01 00:46:47 - browse：71116

European Medicines Agency Suffers Cyber Attack in Amsterdam — Paulo Amorim / VWPics via AP Images

LONDON — European regulators on Friday reiterated their view that an ALS treatment from Amylyx Pharmaceuticals should not be approved, likely dooming the drug’s chances for now.

A European Medicines Agency committee had initially recommended against approving the drug, known as Albrioza, in June. Friday’s confirmation of that position came after the company appealed the decision. While the European Commission officially decides whether to approve a new medicine, it almost always follows the committee’s guidance. The final decision is expected to be made before the end of the year.

The drug, which won approval last year in the United States and is marketed Relyvrio, is designed to slow the progression of the fatal neurological condition. In its pivotal trial, patients who received the drug over 24 weeks scored about two points better on a 48-point scale of symptoms than those who got a placebo, indicating the drug slowed disease progression.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： The cancer drug shortage isn’t new — and neither are the solutions

WSS

Printout prescription drug information shouldn’t go digital

Future doctors need a strong humanities education

The high cost of giving birth even with insurance

United colonoscopy coverage change 'may cost lives,' doctors say

HPV vaccine, cervical cancer study delivers historic results

Peter Hotez and the public health issue of online harassment

explore

leisure time

knowledge

DIEP, the 'gold standard' of breast reconstruction, is under threat

Maisha Meds is a PBM, but don't call it that

In age of alternative facts, a scholarly course on calling out crap

Update the Apgar Score to remove skin color

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Anesthesiologist group: stop taking Ozempic before surgery

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

There's an unseen cost to disruptive road

Duchenne breakthrough therapy leaves behind pioneering families

To bolster infectious disease surveillance, genomics powerhouses team up

knowledge

Maisha Meds is a PBM, but don't call it that

Medicare drug price lawsuits could be good politics for Biden

Future doctors need a strong humanities education

Pumping milk in bathrooms at health conferences is common

Sports medicine is finally prioritizing gender equality

Microsoft launches AI tool for clinical documentation through Epic

focus

focus

focus

entertainment